SCHEMBL30862415

SCHEMBL30862415

C[C@@H](O)[C@H](N)C(=O)NC(=O)[C@@]1(n2cnc3c(N)ncnc32)O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TARS1 P26639 2/20 0.46
▸ ADORA2A P29274 3/20 0.43
▸ ADORA3 P0DMS8 4/20 0.42
▸ PI4KA P42356 2/20 0.42
▸ PI4K2B Q8TCG2 2/20 0.42
▸ PI4K2A Q9BTU6 2/20 0.42
▸ PI4KB Q9UBF8 2/20 0.42
▸ DPP4 P27487 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ SLC28A1 O00337 1/20 0.41
▸ MAP3K7 O43318 1/20 0.41
▸ SLC28A2 O43868 1/20 0.41
▸ GAPDH P04406 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ ADORA2B P29275 1/20 0.41
▸ ADORA1 P30542 1/20 0.41
▸ STAT6 P42226 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ DOT1L Q8TEK3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2185027 1.00 TARS1 (0.46) TARS1ADORA2AADORA3PI4KAPI4K2B
SCHEMBL1275036 1.00 TARS1 (0.46) TARS1ADORA2AADORA3PI4KAPI4K2B
SCHEMBL31675871 0.90 AHCY (0.41) ADORA2AADORA3ADORA2BADORA1DOT1L
SCHEMBL23066313 0.88 ADORA3 (0.45) TARS1ADORA2AADORA3PI4KAPI4K2B
SCHEMBL18011012 0.88 SETD2 (0.44) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL18011010 0.88 SETD2 (0.44) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL157247 0.85 ADORA2A (0.41) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL1300400 0.85 ADORA2A (0.41) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL15798672 0.84 ADORA3 (0.45) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL2480939 0.84 PI4KA (0.46) ADORA2AADORA3PI4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240123078-A1 COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS VIVIDION THERAPEUTICS, INC. 2024-04-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240123078-A1 COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS CD4, ICOS, NFATC1 TARS1 4737/4885ADORA2A 1235/4885ADORA3 2921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback